Page 64 - Read Online

Saliba et al. Cancer Drug Resist 2021;4:125-42 I http://dx.doi.org/10.20517/cdr.2020.95 Page 139

risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
77. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-
risk myelodysplastic syndrome. Leukemia 1997;11:1-5.
78. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III
randomized study. Cancer 2006;106:1794-803.
79. Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk
myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European
Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-96.
80. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:
a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
81. Karon M, Sieger L, Leimbrock S, et al. 5-azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973;42:359-65.
82. Saiki JH, Bodey GP, Hewlett JS, et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a southwest
oncology group study. Cancer 1981;47:1739-42.
83. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in
elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9.
84. Harris NL, Jaffe ES, Diebold J, et al. The world health organization classification of neoplasms of the hematopoietic and lymphoid
tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J 2000;1:53-66.
85. Silverman LR, McKenzie DR, Peterson BL, et al; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients
with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-903.
86. Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the
Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 2014;93:1825-38.
87. Thépot S, Itzykson R, Seegers V, et al; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA);
Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS). Azacitidine in untreated acute myeloid leukemia: a report on
149 patients. Am J Hematol 2014;89:410-6.
88. Hummel-Eisenbeiss J, Hascher A, Hals PA, et al. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the
DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Mol Pharmacol 2013;84:438-50.
89. Wu P, Geng S, Weng J, et al. The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome.
Leuk Res 2015;39:216-20.
90. Brueckner B, Rius M, Markelova MR, et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases
therapeutic drug efficacy. Mol Cancer Ther 2010;9:1256-64.
91. Camiener GW, Smith CG. Studies of the enzymatic deamination of cytosine arabinoside-I. Biochem Pharmacol 1965;14:1405-16.
92. Zauri M, Berridge G, Thézénas ML, et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.
Nature 2015;524:114-8.
93. Eliopoulos N, Cournoyer D, Momparler RL. Drug resistance to 5-aza-2’-deoxycytidine, 2’,2’-difluorodeoxycytidine, and cytosine
arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother
Pharmacol 1998;42:373-8.
94. Beauséjour CM, Eliopoulos N, Momparler L, Le NL, Momparler RL. Selection of drug-resistant transduced cells with cytosine
nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther 2001;8:669-76.
95. Valencia A, Masala E, Rossi A, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of
response to azacitidine. Leukemia 2014;28:621-8.
96. Qin T, Castoro R, El Ahdab S, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 2011;6:e23372.
97. Gruber E, Franich RL, Shortt J, Johnstone RW, Kats LM. Distinct and overlapping mechanisms of resistance to azacytidine and
guadecitabine in acute myeloid leukemia. Leukemia 2020;34:3388-92.
98. Grant S, Bhalla K, Gleyzer M. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor
cells. Leukemia Research 1986;10:1139-46.
99. Grant S, Bhalla K, Gleyzer M. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo
pyrimidine synthesis. Cancer Res 1984;44:5505-10.
100. Itzykson R, Kosmider O, Cluzeau T, et al; Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate
to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147-52.
101. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Blood 2014;124:2705-12.
102. Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and
related neoplasms. Leukemia 2014;28:78-87.
103. Cedena MT, Rapado I, Santos-lozano A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict
response to azacitidine in myelodysplastic syndromes. Oncotarget 2017;8:106948-61.
104. Coombs CC, Sallman DA, Devlin SM, et al. Mutational correlates of response to hypomethylating agent therapy in acute myeloid
leukemia. Haematologica 2016;101:e457-60.
105. Ali A, Penneroux J, Dal Bello R Jr, et al. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic
syndromes and acute myeloid leukemia. Leukemia 2018;32:1856-60.
106. Treppendahl MB, Kristensen LS, Grønbæk K. Predicting response to epigenetic therapy. J Clin Invest 2014;124:47-55.